• Institute of Respiratory Disease,Xinqiao Hospital,Third Military Medical University.Chongqing,400037,China Corresponding author:QIAN Gui-sheng,E-mail:gsqian@mail.tmmu.com.cn;
QIAN Guisheng, Email: gsqian@mail.tmmu.com.cn
Export PDF Favorites Scan Get Citation

Objective  To investigate whether P12,a kind of lipopolysaccharide(LPS)-binding protein(LBP) inhibitory peptide,could suppress the binding of LPS to alveolar macrophages(AMs) in a mouse model of endotoxemia in vivo.Methods  Forty mice were randomly divided into five groups,ie.a control group,an endotoxemia group,a low dose P12-treated group,a middle dose P12-treated group and a high dose P12-treated group.Mouse model of endotoxemia was established by LPS injection intraperitoneally in the endotoxemia group and P12-treated groups.P12 was instilled via the tail vein.The effects of P12 on the binding of LPS to AMs were determined by flow cytometric analysis and quantization by mean fluorescence intensity(MFI).The productions of tumor necrosis factor α(TNF-α) in serum of mice were measured by enzyme-linked immunosorbent assay(ELISA).Results  MFI in AMs from low,middle and high dose P12-treated groups was 40.08%,30.76% and 24.45%,respectively,which was higher than that of the control group(4.61%),but less than that of the endotoxemic mice(45.31%).The concentration of TNF-α in serum of low,media and high dose P12-treated mice was (112.69±19.78)pg/mL,(86.34±9.25) pg/mL,(70.48±8.48)pg/mL respectively,which was higher than that of the control group[(24.88±5.82)pg/mL],but less than that of the endotoxemic mice[(180.17±39.14)pg/mL].Conclusion  The results suggest that P12 inhibit the binding of LPS and AMs,thus reduce the proudction of TNF-α stimulated by LPS.

Citation: WU Xueling,ZHAO Yunfeng,QIAN Guisheng,XU Debin,CHEN Weizhong. Effects of lipopolysaccharide-binding protein inhibitory peptide on the binding of lipopolysaccharide to alveolar macrophages in a mouse model of endotoxemia. Chinese Journal of Respiratory and Critical Care Medicine, 2008, 08(3): 195-198. doi: Copy

  • Previous Article

    Shengmai Injection for Hypoxic-ischemic Encephalopathy: A Systematic Review
  • Next Article

    Representation of Samples in Clinical Trials of Hypertension Medications